Zealand Pharma(GB:0NZU)
kr 241.30-4.60 (-1.87%)
GB:0NZU
Zealand Pharma stock forecast
kr 241.30
At close:-4.60 (-1.87%)
Zealand Pharma (0NZU) Share Forecast & Price Target
18 Followers
0NZU Analyst Ratings
Moderate Buy
1Buy1Hold0Sell
Based on 2 analysts giving stock ratings to Zealand Pharma in the past 3 months
0NZU Stock 12 Month Forecast
Average Price Target
kr 382.50▲(58.52% Upside)Based on 2 Wall Street analysts offering 12 month price targets for Zealand Pharma in the last 3 months. The average price target is DKK 382.50 with a high forecast of DKK 435.00 and a low forecast of DKK 330.00. The average price target represents a 58.52% change from the last price of DKK 241.30.
Past 12 Months12 Month ForecastJan2026Oct2026
Highkr 435.00
Averagekr 382.50
Lowkr 330.00
Highest Price TargetHighestkr 435.00Average Price Targetkr 382.50Lowest Price TargetLowestkr 330.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Yihan Li | Barclays | kr 425→kr 330 | hold | 36.76%Upside | Downgraded | 09/08/26 | ||
| Sophia Graeff Buhl-Nielsen | J.P. Morgan | kr 460→kr 435 | buy | 80.27%Upside | Reiterated | 08/25/26 | ||
| Benjamin Jackson CFA | Jefferies | kr 505→kr 320 | hold | 32.62%Upside | Downgraded | 07/13/26 | ||
| Kerry Holford | Berenberg Bank | kr 825→kr 300 | hold | 24.33%Upside | Downgraded | 06/16/26 | ||
| Emmanuel Papadakis | Deutsche Bank | kr 275→kr 300 | hold | 24.33%Upside | Reiterated | 06/04/26 | ||
| Xian Deng | UBS | kr 730 | buy | 202.53%Upside | Reiterated | 05/08/26 | ||
| Thomas Bowers | SEB Enskilda | kr 380→kr 475 | buy | 96.85%Upside | Upgraded | 04/29/26 | ||
| Martin Brenoe | Nordea Markets | ― | hold | ― | Downgraded | 03/06/26 | ||
| Prakhar Agrawal | Cantor Fitzgerald | ― | hold | ― | Downgraded | 03/06/26 | ||
| Andy Hsieh | William Blair | ― | hold | ― | Downgraded | 03/06/26 | ||
| Kirsty Ross Stewart | Exane BNP Paribas | kr 275 | hold | 13.97%Upside | Downgraded | 03/06/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Yihan LiBarclays | HoldDowngradedkr 425→kr 330 | 09/08/26 | 36.76%Upside | ||
| Sophia Graeff Buhl-NielsenJ.P. Morgan | BuyReiteratedkr 460→kr 435 | 08/25/26 | 80.27%Upside | ||
| Benjamin Jackson CFAJefferies | HoldDowngradedkr 505→kr 320 | 07/13/26 | 32.62%Upside | ||
| Kerry HolfordBerenberg Bank | HoldDowngradedkr 825→kr 300 | 06/16/26 | 24.33%Upside | ||
| Emmanuel PapadakisDeutsche Bank | HoldReiteratedkr 275→kr 300 | 06/04/26 | 24.33%Upside | ||
| Xian DengUBS | BuyReiteratedkr 730 | 05/08/26 | 202.53%Upside | ||
| Thomas BowersSEB Enskilda | BuyUpgradedkr 380→kr 475 | 04/29/26 | 96.85%Upside | ||
| Martin BrenoeNordea Markets | HoldDowngraded | 03/06/26 | ― | ||
| Prakhar AgrawalCantor Fitzgerald | HoldDowngraded | 03/06/26 | ― | ||
| Andy HsiehWilliam Blair | HoldDowngraded | 03/06/26 | ― | ||
| Kirsty Ross StewartExane BNP Paribas | HoldDowngradedkr 275 | 03/06/26 | 13.97%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Zealand Pharma
3 Months
Success Rate1/2 ratings generated profit
50%
Average Return
+7.05%
Copying Thomas Bowers's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.05% per trade.
1 Year
Success Rate1/2 ratings generated profit
50%
Average Return
-6.00%
Copying Thomas Bowers's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -6.00% per trade.
2 Years
Success Rate1/2 ratings generated profit
50%
Average Return
-6.00%
Copying Thomas Bowers's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -6.00% per trade.
0NZU Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 0 |
| Hold | 3 | 3 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 5 | 4 | 3 | 2 | 1 |
In the current month, 0NZU has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0NZU average Analyst price target in the past 3 months is 382.50.
0NZU Financial Forecast
Highkr -8.30
Consensuskr -13.38
Lowkr -19.63
0NZU Earnings Forecast
Next quarter’s earnings estimate for 0NZU is -DKK 13.38 with a range of -DKK 19.63 to -DKK 8.30. The previous quarter’s EPS was -DKK 0.79. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
Highkr 559M
Consensuskr 78.9M
Lowkr 0.00
0NZU Sales Forecast
Next quarter’s sales forecast for 0NZU is DKK 78.89M with a range of DKK 0 to DKK 559.10M. The previous quarter’s sales results were DKK 4.00M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0NZU Stock Forecast FAQ
What is GB:0NZU’s average 12-month price target, according to analysts?
Based on analyst ratings, Zealand Pharma’s 12-month average price target is kr 382.50.
What is GB:0NZU’s upside potential, based on the analysts’ average price target?
Zealand Pharma has 58.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Zealand Pharma a Buy, Sell or Hold?
Zealand Pharma has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is Zealand Pharma’s share price target?
The average share price target for Zealand Pharma is kr 382.50. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is kr 435.00, and the lowest forecast is kr 330.00. The average share price target represents a 58.52% increase from the current price of kr 241.3.
What do analysts say about Zealand Pharma?
Zealand Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Zealand Pharma?
To buy shares of GB:0NZU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
